. Migueles, PhD1,2; Cristina Cadenas-Sanchez, PhD1,3,4,5; David R. Lubans, PhD6,7; et alPontus
A Randomized Clinical TrialDon Laing, MBChB1; Eamon P. G. Walsh, BMedSc1; Jane M. Alsweiler, PhD
A Randomized Clinical TrialLiqiang Zheng, MD, PhD1,2,3; Li Gai, MD4,5; Yani Wu, BS3; et alChaonan
仅用于向医疗卫生专业人士提供科学信息,不代表平台立场审批编码:PP-IX-CN-4047 获批日期:2024年5月24日参考文献[1]https://immunology.knowledgehub
既往的试验表明,与化学免疫治疗相比,不可逆 BTK 抑制剂伊布替尼(I)和BCL-2抑制剂维奈克拉(V)可改善 CLL 结局。I 和 V 靶向 CLL 的两个关键病理生理通路,具有协同作用。这得到
Wang, PhD, MS1; Gowtham Asokan, MS2; Jukka-Pekka Onnela, DSc2; et alDonna D. Baird, PhD3; Anne
Aris, PhD1; Wei Perng, PhD2,3; Dana Dabelea, MD, PhD2,3,4; et alAmy M. Padula, PhD5; Akram
AnalysisTilmann Schober, MD1,2; Kimberly Wong, MD1,3; Gaëlle DeLisle, MScPH1,4; et alChelsea Caya
Jin, MD, MPH1; Ronilda Lacson, MD, PhD2; Mahsa Eskian, MD2; et alJulia McNabb-Baltar, MD, MPH1;